Literature DB >> 22147798

Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.

Jennifer Steele1, Kevin Chen, Xingmin Sun, Yongrong Zhang, Haiying Wang, Saul Tzipori, Hanping Feng.   

Abstract

BACKGROUND: Clostridium difficile infection (CDI) can cause a wide range of disease, from mild diarrhea to fulminant systemic disease. The incidence of systemic CDI with fatal consequence has increased rapidly in recent years.
METHODS: Using an ultrasensitive cytotoxicity assay, we measured C. difficile toxin A (TcdA) and C. difficile toxin B (TcdB) in sera and body fluids of piglets and mice exposed to C. difficile to investigate the relationship between the presence of toxins in body fluids and systemic manifestations of CDI.
RESULTS: We found that both TcdA and TcdB disseminate systemically, with toxins present in the sera and body fluids of infected animals, and toxemia is significantly correlated with the development of systemic CDI. The systemic administration of neutralizing antibodies against both toxins blocked the development of systemic disease in mice. We measured cytokine concentrations in the sera of mice and piglets with systemic and nonsystemic CDI and found that proinflammatory mediators were considerably elevated in animals with systemic CDI.
CONCLUSION: Our study demonstrates the existence of a strong correlation between toxemia and the occurrence of systemic disease, supporting the hypothesis that systemic CDI is most likely due to the toxicity of TcdA and TcdB and the induction of proinflammatory cytokines by the toxins.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22147798      PMCID: PMC3256947          DOI: 10.1093/infdis/jir748

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay.

Authors:  S Johnson; S A Kent; K J O'Leary; M M Merrigan; S P Sambol; L R Peterson; D N Gerding
Journal:  Ann Intern Med       Date:  2001-09-18       Impact factor: 25.391

2.  IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes.

Authors:  J K Linevsky; C Pothoulakis; S Keates; M Warny; A C Keates; J T Lamont; C P Kelly
Journal:  Am J Physiol       Date:  1997-12

3.  Pseudomembranous colitis: report of a severe case with unusual clinical signs in a young nurse.

Authors:  A Boaz; M Dan; I Charuzi; O Landau; Y Aloni; S Kyzer
Journal:  Dis Colon Rectum       Date:  2000-02       Impact factor: 4.585

4.  The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives.

Authors:  Glen P Carter; Julian I Rood; Dena Lyras
Journal:  Gut Microbes       Date:  2010-01

5.  A rare and unsuspected complication of Clostridium difficile infection.

Authors:  Nissar Shaikh; Marie-Anne Kettern; Yolande Hanssens; Sittana S Elshafie; André Louon
Journal:  Intensive Care Med       Date:  2007-11-20       Impact factor: 17.440

6.  An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins.

Authors:  Xiangyun He; Jufang Wang; Jennifer Steele; Xingmin Sun; Weijia Nie; Saul Tzipori; Hanping Feng
Journal:  J Microbiol Methods       Date:  2009-04-23       Impact factor: 2.363

7.  Extraintestinal Clostridium difficile: 10 years' experience at a tertiary-care hospital.

Authors:  L E Wolf; S L Gorbach; E V Granowitz
Journal:  Mayo Clin Proc       Date:  1998-10       Impact factor: 7.616

8.  Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A.

Authors:  Xiangyun He; Xingmin Sun; Jufang Wang; Xiaoning Wang; Quanshun Zhang; Saul Tzipori; Hanping Feng
Journal:  Infect Immun       Date:  2009-03-23       Impact factor: 3.441

Review 9.  Clostridium difficile bacteremia, Taiwan.

Authors:  Nan-Yao Lee; Yu-Tsung Huang; Po-Ren Hsueh; Wen-Chien Ko
Journal:  Emerg Infect Dis       Date:  2010-08       Impact factor: 6.883

10.  Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium.

Authors:  Guilin Yang; Boping Zhou; Jufang Wang; Xiangyun He; Xingmin Sun; Weijia Nie; Saul Tzipori; Hanping Feng
Journal:  BMC Microbiol       Date:  2008-11-06       Impact factor: 3.605

View more
  48 in total

1.  Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis.

Authors:  Jun Huang; Ciarán P Kelly; Kyriaki Bakirtzi; Javier A Villafuerte Gálvez; Dena Lyras; Steven J Mileto; Sarah Larcombe; Hua Xu; Xiaotong Yang; Kelsey S Shields; Weishu Zhu; Yi Zhang; Jeffrey D Goldsmith; Ishan J Patel; Joshua Hansen; Meijin Huang; Seppo Yla-Herttuala; Alan C Moss; Daniel Paredes-Sabja; Charalabos Pothoulakis; Yatrik M Shah; Jianping Wang; Xinhua Chen
Journal:  Nat Microbiol       Date:  2018-12-03       Impact factor: 17.745

2.  A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice.

Authors:  Zhiyong Yang; Diane Schmidt; Weilong Liu; Shan Li; Lianfa Shi; Jinliang Sheng; Kevin Chen; Hua Yu; Jacqueline M Tremblay; Xinhua Chen; Kurt H Piepenbrink; Eric J Sundberg; Ciaran P Kelly; Guang Bai; Charles B Shoemaker; Hanping Feng
Journal:  J Infect Dis       Date:  2014-03-27       Impact factor: 5.226

3.  Glucosylation Drives the Innate Inflammatory Response to Clostridium difficile Toxin A.

Authors:  Carrie A Cowardin; Brianna M Jackman; Zannatun Noor; Stacey L Burgess; Andrew L Feig; William A Petri
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

4.  Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis.

Authors:  Shan Li; Lianfa Shi; Zhiyong Yang; Yongrong Zhang; Gregorio Perez-Cordon; Tuxiong Huang; Jeremy Ramsey; Numan Oezguen; Tor C Savidge; Hanping Feng
Journal:  Infect Immun       Date:  2014-11-17       Impact factor: 3.441

5.  TPL2 Is a Key Regulator of Intestinal Inflammation in Clostridium difficile Infection.

Authors:  Yuanguo Wang; Shaohui Wang; Ciaran P Kelly; Hanping Feng; Andrew Greenberg; Xingmin Sun
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

6.  MBX-500 is effective for treatment of Clostridium difficile infection in gnotobiotic piglets.

Authors:  Jennifer Steele; Quanshun Zhang; Gillian Beamer; Michelle Butler; Terry Bowlin; Saul Tzipori
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

7.  A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.

Authors:  Nicola L Davies; Joanne E Compson; Brendon Mackenzie; Victoria L O'Dowd; Amanda K F Oxbrow; James T Heads; Alison Turner; Kaushik Sarkar; Sarah L Dugdale; Mark Jairaj; Louis Christodoulou; David E O Knight; Amanda S Cross; Karine J M Hervé; Kerry L Tyson; Hanna Hailu; Carl B Doyle; Mark Ellis; Marco Kriek; Matthew Cox; Matthew J T Page; Adrian R Moore; Daniel J Lightwood; David P Humphreys
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

8.  Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.

Authors:  Zhiyong Yang; Jeremy Ramsey; Therwa Hamza; Yongrong Zhang; Shan Li; Harris G Yfantis; Dong Lee; Lorraine D Hernandez; Wolfgang Seghezzi; Jamie M Furneisen; Nicole M Davis; Alex G Therien; Hanping Feng
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

9.  Coordination between T helper cells, iNKT cells, and their follicular helper subsets in the humoral immune response against Clostridium difficile toxin B.

Authors:  Pragya Rampuria; Gillian A Lang; T Scott Devera; Casey Gilmore; Jimmy D Ballard; Mark L Lang
Journal:  J Leukoc Biol       Date:  2016-08-26       Impact factor: 4.962

Review 10.  Variations in virulence and molecular biology among emerging strains of Clostridium difficile.

Authors:  Jonathan J Hunt; Jimmy D Ballard
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.